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Background:  Considerable  research  has  identiﬁed  barriers  to  antenatal  inﬂuenza  vaccination,  yet  no
research  has  explored  temporal  trends  in reasons  for non-receipt.
Purpose:  To  examine  trends  in  reasons  for non-receipt  of  inﬂuenza  vaccination  during  pregnancy.
Methods:  Serial  cross-sectional  analyses  using  8 years  of Georgia  Pregnancy  Risk  Assessment  Monitoring
Survey  (PRAMS)  data  were  conducted.  Weighted  logistic  regression  was  used  to  examine  trends  in the
prevalence  of  citing  reasons  for non-receipt  over  time.
Results:  Between  2004  and 2011,  8300  women  reported  no  inﬂuenza  vaccination  during  or  immediately
before  pregnancy.  Proportions  of women  citing  “doctor  didn’t  mention  vaccination,”  “in ﬁrst  trimester
during  inﬂuenza  season,”  and  “not  pregnant  during  inﬂuenza  season”  decreased  signiﬁcantly  over  time
(Doctor  didn’t  mention:  48.0%  vs. 27.1%,  test  for trend  p < 0.001;  in  ﬁrst  trimester:  26.8% vs.  16.3%, test  for
trend  p <  0.001;  not  inﬂuenza  season:  24.2%  vs. 12.7%,  test  for trend  p =  0.001).  Safety  concerns  increased
over  2004  proportions  in  2010  (concern  about  side  effects  for me:  40.2%  vs.  28.5%, prevalence  ratio
(PR):  1.41,  95% conﬁdence  interval  (CI):  1.16,  1.71;  concern  about  harming  my  baby:  38.9%  vs. 31.0%,
PR  = 1.26,  95%  CI: 1.04,  1.53)  and  2011  (concern  about  side  effects  for  me:  39.0%  vs. 28.5%,  PR  =  1.37,  95%
CI:  1.13,  1.65;  concern  about  harming  my  baby:  38.8%  vs. 31.0%,  PR  =  1.25,  95% CI: 1.04, 1.50).  Following
the  2009/2010  H1N1  pandemic,  more  Hispanic  women  cited  concern  about  vaccination  harming  their
baby  than other  women;  in 2011,  their  concern  remained  elevated  relative  to  non-Hispanic  white  women
(63%  vs.  35%;  adjusted  PR  =  1.79,  95% CI:  1.23,  2.61).
Conclusion:  Examining  trends  in reasons  for non-receipt  of  antenatal  inﬂuenza  vaccination  can  reﬂect
successes  related  to vaccine  promotion  and areas  for improvement.  By  highlighting  differential  impacts
of the  2009/2010  H1N1  pandemic,  we  reveal  opportunities  for  additional  research  on  tailoring  vaccine
promotion  efforts  to  speciﬁc  types  of  women.
ublis©  2016  The  Authors.  P. Introduction
Inﬂuenza vaccination has been recommended for all pregnant
omen regardless of trimester since 2004 [1]. Despite research
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demonstrating increased risks of hospitalization and death from
inﬂuenza-related complications, achieving high vaccination rates
among this population has been challenging [2–4]. Considerable
research has explored why women  do not get vaccinated, and rea-
sons for non-receipt range from concerns about the safety of the
vaccine to perceptions of not being susceptible to inﬂuenza [5–9].
Additional reasons like inadequate knowledge of the beneﬁts of
antenatal vaccination and lack of a provider’s recommendation
for the vaccine have highlighted clear education-related gaps and
opportunities for intervention [10,11]. Initiatives fostering clinical
promotion of antenatal vaccination have resulted in increases in
antenatal vaccination rates [12], and with the 2009/2010 H1N1
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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andemic amplifying awareness of maternal vulnerability and the
eed for protection, national antenatal inﬂuenza vaccination cov-
rage estimates increased from 35% in 2008–2009 to nearly 50% in
009–2010 [13,14].
Since the H1N1 pandemic, however, antenatal vaccination rates
ave plateaued. National antenatal coverage estimates for the 5
nﬂuenza seasons following the pandemic have remained around
0% [15–17]. While studies have explored trends in antenatal
accine coverage rates [6,13,18,19], no research has explored tem-
oral changes in reasons women cite for not getting vaccinated
uring pregnancy. Valuable insights may  be garnered from explor-
ng these trends; for example, changes in reasons for non-receipt
ould identify contemporary gaps that could guide development
f interventions aimed at improving vaccine coverage in the post-
1N1 era. Using 8 years of data from the Georgia Pregnancy Risk
ssessment and Monitoring (PRAMS) survey, this study identi-
es prevalence trends in reasons women cite for not receiving an
nﬂuenza vaccination during pregnancy, determines whether these
rends differ by certain maternal characteristics, and assesses any
nﬂuence the 2009/2010 H1N1 pandemic may  have had on the
on-receipt proﬁle.
. Methods
Data are from the Georgia Pregnancy Risk Assessment and Mon-
toring (PRAMS) survey. PRAMS is a collaboration between the
enters for Disease Control and Prevention (CDC) and participating
ealth departments that collects population-based, state-speciﬁc
nformation on women’s experiences and behaviors before, dur-
ng, and after pregnancy [20]. Participants’ responses are linked
o their infants’ birth certiﬁcates, so data collected through PRAMS
upplements information recorded on birth certiﬁcates. The survey
mploys a stratiﬁed random sampling method among all women
ith a recent live birth in a given state 2–6 months post-partum.
rom 2004 to 2008, PRAMS required a response rate of ≥70% to
elease the data; from 2009 to 2011, they required ≥65% response
ate.
To account for oversampling of women of certain races, from
ertain counties and having infants with low birth weights, data
rom each year were weighted according to the oversampling strat-
gy used for that year. Weights were calculated and provided by the
eorgia Department of Public Health.
To explore temporal trends in the prevalence of reasons cited for
on-receipt, a serial cross-sectional approach was taken to examine
hanges in the annual proportions of women citing speciﬁc rea-
ons for non-receipt of inﬂuenza vaccination during pregnancy.
nly women who indicated not receiving an inﬂuenza vaccina-
ion during their most recent pregnancy were instructed to answer
he question “What were your reasons for not getting a ﬂu vac-
ination during your most recent pregnancy?” Response choices
ncluded: “My  doctor didn’t mention anything about a ﬂu vaccina-
ion during pregnancy,” “I was worried about side effects of the
u vaccination for me,” “I was worried that the ﬂu vaccination
ight harm my  baby,” “I wasn’t pregnant during the ﬂu season
November–February),” “I was in my  ﬁrst trimester during the ﬂu
eason (November–February),” “I don’t normally get a ﬂu vacci-
ation,” and “Other (please specify).” For each response choice,
omen were instructed to circle “Yes” if the reason applied to
hem or “No” if it did not. Thus, women could report multiple rea-
ons for why they were not vaccinated. Thirty-nine women who
id not answer the question about inﬂuenza vaccine receipt but
nswered any or all of the questions about reasons for non-receipt
ere recoded as not having received an inﬂuenza vaccine during
regnancy. Linear trends in the prevalence of citing certain rea-
ons for non-receipt were determined by combining data frome 34 (2016) 1597–1603
all years and modeled using weighted logistic regression with an
ordinal variable for survey year. We also modeled year as an inde-
pendent categorical variable to compare proportions of reasons for
non-receipt between years.
To assess bivariate associations between maternal charac-
teristics and reasons for non-receipt over time, the following
maternal characteristics were assessed: age (≤19, 20–24, 25–29,
30–34, ≥35), education attained (<12 years, 12 years, >12
years), race/ethnicity (non-Hispanic white, non-Hispanic black,
non-Hispanic Asian/other, Hispanic), prenatal insurance status
(Medicaid/No private insurance, At least some private/military
insurance, None), and urban/rural residence. If no information was
provided about prenatal insurance coverage, insurance status at
delivery was substituted as a proxy for prenatal insurance coverage.
Reasons for non-receipt exhibiting a linear association between
annual prevalence and time were modeled using weighted logistic
regression with a variable for the characteristic, an ordinal variable
for year and a (characteristic x year) interaction term. For reasons
not demonstrating a linear association between annual prevalence
and time, dummy  variables for each year were included so as to
examine individual interactions between each year and a given
maternal characteristic. Any model for which the (characteristic
x year) interaction term resulted in a statistically signiﬁcant Wald-
test was considered to have signiﬁcant differences in the trends of
citing that reason across levels of the maternal characteristic.
To determine the impact of the 2009/2010 H1N1 inﬂuenza
pandemic on the non-receipt proﬁle, we re-ran each of the
aforementioned weighted logistic regression models exploring
associations between each maternal characteristic and each rea-
son for non-receipt with a dummy  variable for pandemic. While
we retained an ordinal variable for year in each model to account
for secular trends in citing a given reason for non-receipt, we
substituted the (characteristic x year) interaction term for a (char-
acteristic x pandemic) interaction term. Women  who gave birth
before 09/01/2009 were considered as pregnant pre-pandemic;
women who  gave birth on or after this date were considered as
pregnant during or post-pandemic. While pandemic vaccines did
not became available in Georgia until mid  to late October 2009, the
2009/2010 seasonal vaccine was available by September. Women
giving birth in the interval of time between seasonal vaccine avail-
ability and pandemic vaccine availability would not have had the
opportunity to receive the H1N1 vaccine, but publicity around
H1N1 inﬂuenza over summer 2009 could have inﬂuenced their
decision to also receive the seasonal vaccine. The 47% median
coverage rate for seasonal inﬂuenza vaccination among pregnant
women during the 2009/2010 compared to 35% coverage during the
2008/2009 season supports this hypothesis [21]. For any model in
which the (characteristic x pandemic) interaction term resulted in a
signiﬁcant Wald-test, the pandemic was  considered to have signif-
icant differential effects across levels of the maternal characteristic
on the proportions of women  citing that reason for non-receipt.
Finally, to ascertain each maternal characteristic’s association
with each reason for non-receipt, we limited analyses to 2011 data
in order to reﬂect a more current state of these associations given
contemporary societal and policy contexts surrounding maternal
inﬂuenza vaccination. All 5 maternal characteristics were included
in each weighted logistic regression model for each reason for non-
receipt.
Results of all weighted logistic regression models are reported
as prevalence ratios and 95% conﬁdence intervals unless other-
wise noted. In interaction models, Wald test p-values assessing
the signiﬁcance of interaction terms were adjusted using the
Holm–Bonferroni correction to account for multiple hypothesis
tests run on the data [22]. SAS version 9.3 (Cary, NC) and SAS-
callable SUDAAN version 11.0.1 (Research Triangle Park, NC) were
used to conduct analyses accounting for the complex survey
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tig. 1. Proportions of women  in Georgia who  reported not receiving an inﬂuenza
accine immediately before or during pregnancy, Georgia PRAMS, 2004–2011.
esign and to generate prevalence ratios using predicted marginal
roportions. This study was approved by the Institutional Review
oards of the Georgia Department of Public Health and Emory Uni-
ersity.
. Results
The study sample consisted of 8300 women who  did not receive
n inﬂuenza vaccination immediately before or during pregnancy
etween 2004 and 2011. The distributions of women by age and
ducation level did not vary signiﬁcantly over these 8 years; how-
ver, compared to other years, the proportions of Hispanic women
ere greater in 2008 and 2009, the proportion of women  citing no
nsurance was  higher in 2008, and the proportion of women living
n rural areas was higher in 2007 [Table 1].
Between 2004 and 2011, the proportion of women not receiv-
ng an antenatal inﬂuenza vaccine decreased over time (88.9% in
004 vs. 64.2% in 2011, test for trend p < 0.001) [Fig. 1]. Of the total
ample, 7983 (96.2%) provided at least one reason for not receiv-
ng an inﬂuenza vaccine during pregnancy. Despite the signiﬁcant
ecreases in unvaccinated women during this time period, the most
requently cited reason for non-receipt across all years was  “I don’t
ormally get a ﬂu vaccine [Fig. 2F]. Among women citing this rea-
on, 34% cited no additional reason.
The prevalence of women citing that their doctor didn’t men-
ion vaccination, that they were in their ﬁrst trimester, and that
hey were not pregnant during inﬂuenza season all decreased sig-
iﬁcantly over time (Doctor didn’t mention: 48.0% in 2004 vs. 27.1%
n 2011, test for trend p < 0.001; In ﬁrst trimester: 26.8% in 2004 vs.
6.3% in 2011, test for trend p < 0.001; not inﬂuenza season 24.2%
n 2004 vs. 12.7% in 2011, test for trend p = 0.001) [Fig. 2A–C]. The
roportion of women citing concern about side effects for them-
elves and concern about harming their baby declined or remained
elatively stable through 2009 then increased signiﬁcantly over
004 proportions in 2010 (Concern about side effects for me:  40.2%
s. 28.5%, PR = 1.41, 95% CI: 1.16, 1.71; concern about harming
y  baby: 38.9% vs. 31.0%, PR = 1.26, 95% CI: 1.04, 1.53) and 2011
Concern about side effects for me:  39.0% vs. 28.5%, PR = 1.37, 95%
I: 1.13, 1.65; concern about harming my  baby: 38.8% vs. 31.0%,
R = 1.25, 95% CI: 1.04, 1.50) [Fig. 2D and E].
Of the three reasons for non-receipt whose yearly proportions
howed a linear decrease over time, two interaction models pro-
uced signiﬁcant (year x maternal characteristic) interactions. For
iting “in my  ﬁrst trimester during ﬂu season,” Hispanic women
ent from being the least likely racial/ethnic group to cite this rea-
on in 2004 to the most likely group in 2011, while proportions
f both non-Hispanic black and non-Hispanic white women citing
his reason decreased over time [Fig. 3]. For citing “not pregnante 34 (2016) 1597–1603 1599
during inﬂuenza season,” uninsured women  started citing this rea-
son more beginning in 2009 than privately-insured women or
women on Medicaid [Supplemental Fig. A].
Of the two  reasons for non-receipt whose yearly proportions
showed a U-shaped association with time, only the interaction
model examining an association between race/ethnicity and citing
concern about harming the baby showed signiﬁcant heterogeneity
across years [Fig. 3B]. Beginning in 2009, Hispanic women  started
becoming more likely to cite concern about harming the baby than
women of other races, with the interaction term between Hispanic
race and year becoming highly signiﬁcant in 2011 (p = 0.008).
Of models exploring interactions between selected maternal
characteristics and the 2009/2010 H1N1 pandemic, only the model
examining an association between insurance status and citing doc-
tor did not mention vaccination exhibited signiﬁcant interaction
between insurance status and the pandemic (p = 0.005). Compared
to women with at least some private health insurance, women
without any insurance were more likely to cite their doctor not
mentioning vaccination after the pandemic than before (Pre- vs.
post-pandemic prevalences for insured women: 45% vs. 37%; pre
vs. post-pandemic prevalences for women without insurance: 35%
vs. 50%). Eight other models contained a signiﬁcant interaction term
between a given maternal characteristic and the pandemic dummy
variable prior to the Holm–Bonferroni correction [Supplementary
Table A]. Note that no models testing differential impacts of the
pandemic by levels of the ﬁve selected maternal characteristics
were signiﬁcant for citing “worried about side effects for me” or
“I don’t normally get an inﬂuenza vaccine” (data not shown).
In 2011, women less than 20 years old were more likely to
cite that their doctor did not mention ﬂu vaccination than women
aged 25–29 years old (PR = 1.71, 95% CI: 1.10, 2.67) [Table 2]. Non-
Hispanic Asian/other women  were over twice as likely to cite
the doctor did not mention vaccination than non-Hispanic white
women (PR = 2.03, 95% CI: 1.03, 3.99). Signiﬁcantly more Hispanic
women cited concern about harming their baby than non-Hispanic
white women (PR = 1.79, 95% CI: 1.23, 2.61), and women aged 20–24
were signiﬁcantly less likely than 25–29 year olds to cite that they
were not pregnant during inﬂuenza season (PR = 0.35, 95% CI: 0.13,
0.95).
4. Discussion
The number of women in Georgia who declined ﬂu vaccina-
tion during pregnancy dropped signiﬁcantly between 2004 and
2011, and the reasons women  cited for not getting vaccinated
changed between 2004 and 2011. The prevalence of citing “doctor
did not mention vaccination” declined steadily over time, presum-
ably as more obstetricians and women became familiar with the
recommendation to promote and receive this vaccine during preg-
nancy. Likewise, a similar decline is observed in the proportions
of women citing their ﬁrst trimester as a reason for non-receipt,
a ﬁnding which not only aligns with the 2004 endorsement of
the safety of the inﬂuenza vaccine during any trimester [1], but
with concomitant increases in coverage among women in their
ﬁrst trimester [18]. From a public health policy perspective these
trends are positive as they likely reﬂect success of efforts to increase
provider-patient discussions of antenatal inﬂuenza vaccination and
awareness of the vaccine’s safety. But in the post-H1N1 era as pub-
lic health practitioners and vaccine advocates aim to surpass 50%
antenatal inﬂuenza vaccine coverage, it is worth exploring these
trends in more depth to identify potential areas for improvement
in antenatal vaccine promotion.
Across all years, the most frequently cited reason for non-receipt
was “I don’t normally get an inﬂuenza vaccine.” Numerous stud-
ies have identiﬁed a correlation between prior seasonal inﬂuenza
1600 A.T. Chamberlain et al. / Vaccine 34 (2016) 1597–1603
Table  1
Weighted distributions of maternal characteristics by year among women  indicating no inﬂuenza vaccine receipt during or immediately before pregnancy, Georgia Pregnancy
Risk  Assessment Monitoring Survey (PRAMS), 2004–2011.
Survey year
2004
(n = 1384)
No. (%)
2005
(n = 1476)
No. (%)
2006
(n = 1661)
No. (%)
2007
(n = 584)
No. (%)
2008
(n = 802)
No. (%)
2009
(n = 604)
No. (%)
2010
(n = 709)
No. (%)
2011
(n = 1078)
No. (%)
pa
Maternal age (years) 0.81
≤19 158 (9.5) 191 (10.6) 210 (11.8) 71 (12.6) 86 (11.4) 94 (14.2) 99 (10.7) 356 (11.8)
20–24  378 (26.7) 430 (29.5) 464 (29.1) 153 (26.3) 235 (28.2) 178 (30.1) 220 (29.9) 237 (28.5)
25–29  368 (27.6) 373 (26.5) 443 (26.9) 137 (26.7) 217 (28.4) 147 (25.7) 176 (25.0) 226 (30.9)
30–34  281 (21.2) 321 (23.1) 334 (20.1) 126 (20.3) 148 (19.8) 121 (19.3) 146 (24.2) 156 (18.6)
≥35 199 (15.0) 161 (10.3) 210 (12.1) 97 (14.2) 116 (12.2) 64 (10.7) 68 (10.2) 103 (10.2)
Missing 0 0 0 0 0 0 0 0
Maternal education 0.52
<12  years 269 (22.7) 313 (22.9) 225 (15.9) 103 (17.4) 149 (22.3) 119 (21.4) 146 (19.7) 295 (19.7)
12  years 441 (29.8) 488 (32.4) 529 (35.5) 210 (36.2) 259 (32.5) 181 (34.4) 237 (35.3) 363 (33.6)
>12  years 650 (47.6) 644 (44.7) 746 (48.6) 250 (46.4) 364 (45.2) 270 (44.2) 311 (45.1) 383 (46.7)
Missing 24 31 161 21 30 34 15 37
Race/Ethnicity <0.0001
Non-Hispanic white 523 (51.6) 531 (50.9) 608 (49.6) 230 (49.3) 277 (39.8) 215 (41.6) 279 (43.1) 464 (49.9)
Non-Hispanic black 690 (31.5) 768 (33.1) 847 (33.8) 257 (29.8) 292 (29.1) 259 (33.5) 342 (36.7) 457 (32.8)
Non-Hispanic Asian/other 36 (1.9) 43 (3.1) 40 (3.5) 23 (6.1) 111 (11.1) 31 (4.8) 27 (6.3) 35 (3.6)
Hispanic 117 (15.0) 118 (12.9) 140 (13.1) 63 (14.8) 106 (20.0) 84 (20.1) 56 (13.9) 108 (13.6)
Missing 18 16 26 11 16 15 5 14
Prenatal insurance status 0.004
Medicaid/No private 692 (45.0) 781 (46.4) 863 (48.3) 281 (42.0) 391 (45.6) 306 (51.5) 413 (52.8) 699 (56.3)
At  least some private 631 (47.8) 618 (46.1) 696 (43.8) 254 (48.1) 336 (41.6) 244 (39.8) 234 (36.9) 300 (35.9)
None  55 (7.2) 69 (7.5) 98 (7.9) 46 (9.9) 69 (12.7) 34 (8.6) 43 (10.3) 61 (7.9)
Missing 6 8 4 3 6 20 19 18
Urban/rural residence 0.0001
Urban 1000 (68.7) 985 (69.6) 730 (68.7) 388 (59.2) 642 (73.6) 384 (75.5) 432 (69.9) 685 (70.9)
Rural  384 (31.3) 404 (30.4) 335 (31.3) 196 (40.8) 160 (26.4) 220 (24.5) 277 (30.1) 393 (29.1)
Missing 87 596 0 0 0 0 0 0
Note: Sample sizes reﬂect actual frequencies; percentages are weighted, unadjusted estimates.
a p-Values are based on Rao-Scott 2 tests of the weighted percentages. Bolded p-values indicate signiﬁcance at the 0.05 level.
Table 2
Associations between maternal characteristics and reasons cited for non-receipt of inﬂuenza vaccination during pregnancy, multivariate model, Georgia PRAMS, 2011.
Characteristics Doctor didn’t
mention ﬂu
vaccination during
pregnancy
Worried about side
effects of the ﬂu
vaccine for me
Worried the
vaccine might
harm baby
Wasn’t pregnant
during ﬂu season
(November–February)
In ﬁrst trimester
during ﬂu season
Don’t normally get
a ﬂu vaccination
Maternal age (years) Adjusted PR (95%CI)
<20 1.73 (1.11, 2.70) 0.88 (0.59, 1.30) 1.04 (0.72, 1.51) 0.75 (0.39, 1.43) 0.91 (0.49, 1.67) 0.85 (0.68, 1.06)
20–24  1.17 (0.68, 2.02) 0.97 (0.63, 1.49) 1.01 (0.66, 1.58) 0.35 (0.13, 0.95) 0.65 (0.27, 1.45) 0.94 (0.75, 1.18)
25–29  Ref Ref Ref Ref Ref Ref
30–34  1.01 (0.53, 1.93) 1.02 (0.67, 1.56) 1.16 (0.75, 1.80) 0.70 (0.31, 1.58) 1.16 (0.57, 2.37) 0.96 (0.76, 1.21)
≥35  1.00 (0.42, 2.41) 1.20 (0.74, 1.97) 1.53 (0.99, 2.37) 0.62 (0.18, 2.20) 0.32 (0.07, 1.40) 0.82 (0.58, 1.17)
Maternal education
<12 years 0.82 (0.44, 1.55) 0.66 (0.39, 1.11) 0.71 (0.44, 1.13) 2.04 (0.86, 4.86) 1.48 (0.65, 3.39) 0.97 (0.75, 1.25)
12  years 1.17 (0.73, 1.88) 0.84 (0.58, 1.20) 1.06 (0.76, 1.49) 1.22 (0.51, 2.94) 1.71 (0.86, 3.39) 0.96 (0.79, 1.18)
>12  years Ref Ref Ref Ref Ref Ref
Race/Ethnicity
Non-Hispanic white Ref Ref Ref Ref Ref Ref
Non-Hispanic black 1.16 (0.72, 1.86) 0.95 (0.66, 1.36) 1.05 (0.73, 1.50) 0.86 (0.47, 1.58) 0.77 (0.39, 1.49) 0.93 (0.78, 1.11)
Non-Hispanic Asian/other 2.03 (1.03, 3.99) 1.02 (0.52, 2.02) 1.19 (0.62, 2.30) 1.04 (0.28, 3.82) 1.03 (0.30, 3.52) 0.85 (0.50, 1.45)
Hispanic 1.47 (0.76, 2.83) 1.33 (0.87, 2.05) 1.79 (1.23, 2.61) 0.62 (0.22, 1.76) 1.31 (0.62, 2.77) 0.73 (0.50, 1.07)
Prenatal insurance status
Medicaid/No private 0.94 (0.55, 1.60) 0.70 (0.48, 1.02) 0.73 (0.50, 1.06) 0.78 (0.34, 1.79) 0.79 (0.37, 1.68) 1.05 (0.84, 1.31)
At  least some private Ref Ref Ref Ref Ref Ref
None  1.38 (0.61, 3.08) 0.92 (0.49, 1.71) 0.85 (0.46, 1.58) 2.31 (0.78, 6.82) 1.51 (0.59, 3.87) 1.14 (0.83, 1.56)
Urban/rural residence
Urban Ref Ref Ref Ref Ref Ref
Rural  1.29 (0.85, 1.94) 1.08 (0.78, 1.49) 1.11 (0.82, 1.51) 1.70 (0.93, 3.10) 0.84 (0.47, 1.52) 1.04 (0.88, 1.24)
Bold values indicate signiﬁcance of 95% CI. Models for each reason for non-receipt were adjusted for all the variables in the table. Abbreviations: PRAMS (Pregnancy Risk
Assessment Monitoring System), PR (prevalence ratio), CI (conﬁdence interval), Ref (referent).
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accination. (B) In ﬁrst trimester during inﬂuenza season (November – February). (
ide  effects of vaccination for me.  (E) Worried about harming the baby. (F) Do not n
accine receipt and antenatal receipt, and the predominance of
his reason across time supports these ﬁndings [5]. With over
ne-third of the women citing this reason not citing any addi-
ional reason, delving deeper into why these women do not
ormally get a seasonal inﬂuenza vaccine will be an important step
oward identifying effective interventions. Reasons like believing
nﬂuenza vaccines are ineffective, living a “healthy lifestyle,” orring pregnancy, Georgia PRAMS, 2004–2011. (A) Doctor did not mention inﬂuenza
s  not pregnant during inﬂuenza season (November–February). (D) Worried about
ly get an inﬂuenza vaccine.
perceiving low susceptibility to inﬂuenza are examples of other
reasons frequently cited [11,23], and their absence as explicit
response options on the Georgia PRAMS survey may have inad-
vertently discouraged mentioning these reasons. Response choices
addressing perceived ineffectiveness and low susceptibility to the
disease were subsequently added to Georgia PRAMS beginning
in 2012.
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ig. 3. Trends in the prevalence of citing (A) in my  ﬁrst trimester by race/ethnicity a
The 2009/2010 pandemic appears to have had a considerable
mpact on the non-receipt proﬁle, most notably on concerns about
accine safety. Prior to the pandemic, the prevalence of citing con-
ern about side effects for me  and concern about harming the
aby rarely exceeded 30%. The prevalence of each of these reasons
ncreased signiﬁcantly after the pandemic, reaching or approaching
0%. While the exact reasons for this increase are uncertain, the
ncrease aligns with other reports of increasing hesitancy in regards
o childhood vaccination observed over a similar timeframe [24].
lternatively, it could be an artifact of “reason replacement” fol-
owing the highly publicized prioritization of pregnant women
or vaccination. Since the 2009/2010 H1N1 inﬂuenza pandemic
rompted more obstetricians to recommend vaccination than ever
efore, those remaining unvaccinated were not likely to site knowl-
dge or access-related barriers, but rather other concerns, such as
hose about safety.
While concern about harming the baby increased across all
acial/ethnic groups following the pandemic, the increase was
ighly signiﬁcant for Hispanic women, resulting in a post-pandemic
revalence of 50% that remained signiﬁcantly greater than that
f non-Hispanic white women even into 2011. These ﬁndings
irror those from Freed, et al who found that Hispanic indi-
iduals are more likely to express vaccine safety concerns than
ndividuals of other racial/ethnic groups [25]. Similarly, while the
revalence of citing doctor did not mention vaccination contin-
ed to decline after the pandemic, declines were only signiﬁcant
mong non-Hispanic whites and those privately insured. The pro-
ortion of uninsured women citing this reason rose compared
o women with public or private coverage. These differential
mpacts of the 2009/2010 pandemic corroborate ﬁndings from
ther studies [26], and lend important insights into how women
f different backgrounds recalled or perceived inﬂuenza vacci-
ation after the 2009/2010 pandemic. These results also imply
hat physicians may  have refrained from promoting or offering
he vaccine if they knew a woman could not afford the vaccine
r they were not likely to get reimbursed for administering it.
xploring and understanding the underlying reasons for these dif-
erences will be important to developing targeted, evidence-based
essaging following similar pandemic events affecting pregnant
omen.
While examining trends in reasons for non-receipt is usefulor identifying ways in which high-proﬁle vaccine-related events
ike pandemics can affect these reasons, focusing on more cur-
ent non-receipt proﬁles offers its own important insights. Analysis
f 2011 data again reveals the elevated concern about harmingHispan ic
) concerned about harming my baby by race/ethnicity, Georgia PRAMS, 2004–2011.
the baby on the part of Hispanic women. It also suggests that
the youngest women and Non-Hispanic Asian/other women  are
not recalling doctors mentioning inﬂuenza vaccination. Rectifying
these differences could mean calling physicians’ attention to these
ﬁndings, developing provider-focused interventions that improve
their own knowledge of and conﬁdence in the latest vaccine rec-
ommendations [27], and reiterating the importance of promoting
inﬂuenza vaccination to all pregnant women  regardless of demo-
graphics. However, they could reﬂect a need for more targeted,
evidence-based communication strategies for use with speciﬁc
women. Research in the arena of vaccine messaging has revealed
that vaccine decisions occur within a complex societal framework,
often inﬂuenced by familial opinions and broader social norms [28].
As more targeted messages are developed or reﬁned, they should
move beyond the provision of information to take these more socio-
ecological inﬂuences into account.
This study has some important limitations. First, the PRAMS
questionnaire is only administered to women who had a live birth,
so data on reasons for non-receipt of antenatal inﬂuenza vacci-
nation were not obtained from women experiencing stillbirths.
Additionally, the questionnaire only prompts women who did not
receive an inﬂuenza vaccine follow-up questions on reasons for
non-receipt. While non-receivers are the most important group
on which to public health interventions, understanding why  the
women who got vaccinated chose to do so is also important for
identifying inﬂuential factors. Additionally, it is possible that some
of the women who  chose to vaccinate still had reservations about
vaccination. Without analogous data on concerns from the vacci-
nated women, we were unable to determine the proportion of total
women who  may  have had certain concerns.
While the results are most generalizable to the state of Georgia,
we do not have reason to believe that pregnant women in Georgia
are dramatically different from pregnant women in most other
states. It should be noted though that states can vary on issues
around vaccine coverage and acceptance, so caution should still be
taken in extrapolating ﬁndings from this study to other populations.
For example, Georgia’s antenatal vaccine coverage rates during the
survey years included in this study were lower than the national
coverage estimates during this time period [14,15,17]. Moreover,
compared to non-Hispanic whites and non-Hispanic blacks, the
number of women included from other racial groups was relatively
small; some of the variability seen in the stratiﬁcations by race
could be attributable to small sample sizes. Lastly, we analyzed the
data by survey year, not by inﬂuenza season, so slight variations in
non-receipt trends could be observed if examined across inﬂuenza
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easons. At the time of this analysis, 2012 PRAMS data was not yet
vailable, so we had only 2 inﬂuenza seasons of data following the
1N1 inﬂuenza pandemic to analyze. Including additional years of
ata following the 2009/2010 H1N1 pandemic will be beneﬁcial in
onﬁrming any changes in trends potentially associated with the
andemic.
It is important to note that from December 2009 to December
010, Georgia PRAMS added H1N1-vaccine related supplementary
uestions to the end of the standard questionnaire, however, we
nly used women’s responses to the ﬁrst standard inﬂuenza vacci-
ation questions for our analyses. While the supplement included
uestions differentiating between receipt of the 2009/2010 H1N1
andemic vaccine and the 2009/2010 seasonal inﬂuenza vaccine,
he supplementary questions appeared at the very end of the ques-
ionnaire well after a woman responded to the standard questions
n antenatal inﬂuenza vaccine receipt. Since our primary purpose
as to understand trends in non-receipt among women who did
ot receive any antenatal inﬂuenza vaccinations, and the standard
uestions were not speciﬁc to either vaccine, we  assumed women
nswered the standard questions considering receipt of either, both
r neither vaccine.
As the ﬁrst study to use PRAMS survey data to examine changes
n reasons for non-receipt of antenatal inﬂuenza vaccination over
ime, we can visualize both successes related to clinical vaccine
romotion as well as areas for further improvement. Consistent
eclines in the number of women citing reasons like their doctor
id not mention vaccination and being in their ﬁrst trimester dur-
ng inﬂuenza season indicate progress in overcoming knowledge
aps once identiﬁed as major barriers to antenatal vaccine uptake.
ut a more nuanced view reveals how these trends can differ by
ace, insurance status, or maternal age, and how they can be altered
y high-proﬁle health-related events like the 2009/2010 inﬂuenza
andemic. Using trend data to identify these types of disparities
r conﬁrm ﬁndings from other cross-sectional surveys exploring
easons for non-receipt can reﬁne vaccine promotion efforts. As
ew, targeted promotion efforts are adopted and as more years of
RAMS data are collected, we can continue to track progress toward
ncreasing antenatal coverage and more effectively address reasons
or non-receipt as they arise.
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